Description and Brand Names
Información sobre medicamentos proporcionada por: IBM Micromedex
US Brand Name
- Darzalex Faspro
Descriptions
Daratumumab and hyaluronidase-fihj combination injection is used together with bortezomib, melphalan, and prednisone to treat newly diagnosed multiple myeloma (a type of bone marrow cancer) in patients who cannot receive autologous stem cell transplant (transplant that uses their own stem cells).
Daratumumab and hyaluronidase-fihj combination injection is used together with lenalidomide and dexamethasone to treat newly diagnosed multiple myeloma in patients who cannot receive autologous stem cell transplant. It is also used together with lenalidomide and dexamethasone to treat relapsed (cancer that has come back) or refractory (cancer that did not respond to treatment) multiple myeloma in patients who have received at least 1 previous treatment.
Daratumumab and hyaluronidase-fihj combination injection is used together with bortezomib and dexamethasone to treat multiple myeloma in patients who have received at least 1 previous treatment.
Daratumumab and hyaluronidase-fihj combination injection is also used alone to treat multiple myeloma in patients who have received at least 3 previous treatments or in patients who did not respond to previous treatments. These previous treatments include a proteasome inhibitor and an immunomodulatory agent.
This medicine is to be given only by or under the supervision of your doctor.
This product is available in the following dosage forms:
Portions of this document last updated: July 01, 2020
Copyright © 2020 IBM Watson Health. Todos los derechos reservados. La información es para uso exclusivo del usuario final y no puede venderse, redistribuirse ni utilizarse de ninguna otra forma con fines comerciales.